Tourette Syndrome - Market Insight, Epidemiology and Market Forecast - 2027

albany, NY -- (SBWire) -- 02/01/2019 --Tourette Syndrome - Market Insight, Epidemiology and Market Forecast - 2027

30 Jan. 19

Tourette Syndrome occurs in people from all ethnic groups; males are affected about three to four times more often than females.

1. 1 of every 360 (0.3%) children 6 – 17 years of age in the US have received a diagnosis of Tourette Syndrome
2. The prevalence of Tourette Syndrome in school-age children falls between 5 and 7 cases per 1,000. The prevalence of chronic motor tic disorder in school-age children ranges from 3 to 8 per 1,000, whereas estimates of prevalence for chronic vocal tic disorder are less stable
3. There are approximately 100,000 cases of Tourette Syndrome in the United States, although the prevalence may be much higher if all mild cases of tics are counted

Key benefits

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Tourette Syndrome market
2. Organize sales and marketing efforts by identifying the best opportunities for Tourette Syndrome market
3. To understand the future market competition in the Tourette Syndrome market.

Request for sample pages

"The most patients will have complete or nearly complete remission of the disorder after 21 years of age. In 10–20% of cases, TS symptoms fluctuate, persist, or even worsen"

Tourette Syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The disorder is named after Dr. Georges Gilles de la Tourette, the pioneering French neurologist, who in 1885 had first described the condition in an 86-year-old French noblewoman.

Current pharmacological treatments have provided very limited efficacy and are almost always accompanied by severe side effects. To date only limited drugs are approved by the FDA for the treatment of TS patients. However, exposure to these drugs is associated with side effects, which may limit their tolerability and use in many TS patients.

Companies covered
1. Abide Therapeutics,
2. Teva Pharmaceutical Industries
3. Neurocrine Biosciences
4. Therapix Biosciences
And many others

Drugs covered

1. ABX-1431
2. Deutetrabenazine
3. Valbenazine (Neurocrine
4. THX-110
And many others

Key topics covered

1. Report Introduction
2. Tourette Syndrome Market Overview at a Glance
2.1. Market Share Distribution of Tourette Syndrome in 2017
2.2. Market Share Distribution of Tourette Syndrome in 2027
3. Disease Background and Overview: Tourette Syndrome
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Tourette Syndrome in 7MM
4.3. Total Prevalent Patient Population of Tourette Syndrome in 7MM – By Countries
5. Epidemiology of Tourette Syndrome by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Tourette Syndrome
5.1.3. Sub-Type Specific cases of the Tourette Syndrome *
5.1.4. Sex- Specific Cases of the Tourette Syndrome *
5.1.5. Diagnosed Cases of the Tourette Syndrome
5.1.6. Treatable Cases of the Tourette Syndrome
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Tourette Syndrome
5.4.3. Sub-Type Specific cases of the Tourette Syndrome *
5.4.4. Sex- Specific Cases of the Tourette Syndrome *
5.4.5. Diagnosed Cases of the Tourette Syndrome
5.4.6. Treatable Cases of the Tourette Syndrome
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Tourette Syndrome
5.5.3. Sub-Type Specific cases of the Tourette Syndrome *
5.5.4. Sex- Specific Cases of the Tourette Syndrome *
5.5.5. Diagnosed Cases of the Tourette Syndrome
5.5.6. Treatable Cases of the Tourette Syndrome
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Tourette Syndrome
5.6.3. Sub-Type Specific cases of the Tourette Syndrome *
5.6.4. Sex- Specific Cases of the Tourette Syndrome *
5.6.5. Diagnosed Cases of the Tourette Syndrome
5.6.6. Treatable Cases of the Tourette Syndrome
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Tourette Syndrome
5.7.3. Sub-Type Specific cases of the Tourette Syndrome *
5.7.4. Sex- Specific Cases of the Tourette Syndrome *
5.7.5. Diagnosed Cases of the Tourette Syndrome
5.7.6. Treatable Cases of the Tourette Syndrome
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Tourette Syndrome
5.8.3. Sub-Type Specific cases of the Tourette Syndrome *
5.8.4. Sex- Specific Cases of the Tourette Syndrome *
5.8.5. Diagnosed Cases of the Tourette Syndrome
5.8.6. Treatable Cases of the Tourette Syndrome
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Tourette Syndrome
5.9.3. Sub-Type Specific cases of the Tourette Syndrome *
5.9.4. Sex- Specific Cases of the Tourette Syndrome *
5.9.5. Diagnosed Cases of the Tourette Syndrome
5.9.6. Treatable Cases of the Tourette Syndrome
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Tourette Syndrome
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Tourette Syndrome
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Tourette Syndrome : 7MM Market Analysis
12.1. 7MM Market Size of Tourette Syndrome
12.2. 7MM Percentage Share of drugs marketed for Tourette Syndrome
12.3. 7MM Market Sales of Tourette Syndrome by Products
13. Tourette Syndrome : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Tourette Syndrome in United States
13.1.2. Percentage Share of drugs marketed for Tourette Syndrome in United States
13.1.3. Market Sales of Tourette Syndrome by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Tourette Syndrome in Germany
13.2.1.2. Percentage Share of drugs marketed for Tourette Syndrome in Germany
13.2.1.3. Market Sales of Tourette Syndrome by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Tourette Syndrome in France
13.2.2.2. Percentage Share of drugs marketed for Tourette Syndrome in France
13.2.2.3. Market Sales of Tourette Syndrome by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Tourette Syndrome in Italy
13.2.3.2. Percentage Share of drugs marketed for Tourette Syndrome in Italy
13.2.3.3. Market Sales of Tourette Syndrome by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Tourette Syndrome in Spain
13.2.4.2. Percentage Share of drugs marketed for Tourette Syndrome in Spain
13.2.4.3. Market Sales of Tourette Syndrome by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Tourette Syndrome in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Tourette Syndrome in United Kingdom
13.2.5.3. Market Sales of Tourette Syndrome by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Tourette Syndrome in Japan
13.3.2. Percentage Share of drugs marketed for Tourette Syndrome in Japan
13.3.3. Market Sales of Tourette Syndrome by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20.About DelveInsight